N@N

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the U.S. launch and first commercial sales of MEDIHONEY HCS (Hydrogel Colloidal Sheet), the latest in the MEDIHONEY line of advanced wound care products. MEDIHONEY HCS is a patented dressing comprising a combination of the Companyas MEDIHONEY and XTRASORB HCS dressings. The product will be available for the treatment of first- and second-degree burns, in addition to various chronic and acute wounds.

MEDIHONEY HCS will be highlighted at the Symposium on Advanced Wound Care (SAWC) Meeting in Baltimore September 12^th-14^th. Derma Sciences will be highlighting the productas two mechanisms of action, high osmoloarity and low pH, at booth #1316. Also being exhibited is the productas ability, because of the Super Absorbent Polymer technology, to help modulate MMPs from the wound environment. MMPs are protease enzymes that cause delayed healing. This combination dressing will be able to handle up to 2.5 times the amount of fluid of market-leading hydrocolloids, while also providing a moist environment for dry wounds.

aThe marriage of our leading products drove the development of MEDIHONEY HCS and provides us with deeper penetration of the market for burn treatments. MEDIHONEY HCS, our fifth MEDIHONEY line extension, is a smart dressing that helps to hydrate dry wounds and absorb fluid from those that are draining. We are thrilled now to be able to encourage its use amongst the medical community,a stated Ed Quilty, CEO of Derma Sciences. aMEDIHONEY HCS will provide physicians and caretakers with an additional novel next-generation advanced wound dressing to help optimize their clinical outcomes, while greatly increasing the versatility of the MEDIHONEY brand. We plan to take this product to our domestic OTC customers and look forward to launching MEDIHONEY HCS in Europe early next year.a

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, BIOGUARD for infection prevention and TCC-EZa", a gold-standard treatment for diabetic foot ulcers.

For more information please visit [ www.dermasciences.com ].

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as amay,a awill,a aexpect,a abelieve,a aanticipate,a aintend,a acould,a aestimatea or acontinuea are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.